Primary vaccination with Beta-containing vaccine candidate delivers 64.7% efficacy against symptomatic infection in adults, and 75.1% efficacy in participants previously infected with COVID-19 Against Omicron, sequencing analysis performed to date shows 72% efficacy in all adults and 93.2% in seropositives Favorable safety and tolerability profile
COVID-19 vaccine: Sanofi, GSK report robust immune response in early-stage trials
Monday s announcement, however, comes as a relief for Sanofi and GSK after they were forced last December to restart their trial and delay the launch of the shot when the vaccine showed a low immune response in older adults as a result of a weak antigen formulation
Reuters | May 17, 2021 | Updated 14:21 IST
An experimental COVID-19 vaccine developed by Sanofi and GlaxoSmithKline showed a robust immune response in early-stage clinical trial results, enabling them to move to a late-stage study, the French drugmaker said on Monday.
Sanofi and Britain s GSK said a global Phase III trial would start in the coming weeks and involve more than 35,000 adults, with the hope of seeing the vaccine approved by the fourth quarter after having initially targeted the first half of this year before a setback.